Last reviewed · How we verify
NCT03062826
EROSION II: OCT Guided PPCI in STEMI
trial testing dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) in ST-segment Elevation Myocardial Infarction in 347 participants. Status unknown.
24 February 2022
Quick facts
| Lead sponsor | Harbin Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 347 |
| Start date | 11 January 2017 |
| Primary completion | 24 February 2022 |
| Estimated completion | 1 March 2023 |
| Sites | 16 locations across China |
Drugs / interventions tested
- dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) — full drug profile →
Conditions studied
- ST-segment Elevation Myocardial Infarction — all drugs for ST-segment Elevation Myocardial Infarction →
Sponsor
Harbin Medical University
Who can join
Adults 18 to 75, any sex, with ST-segment Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This protocol describes a prospective, multi-center study intended to test the hypothesis that patients with STEMI caused by plaque rupture or plaque erosion without obstructive stenosis (diameter stenosis \<70%) can be stabilized by effective antithrombotic treatment without stent implantation, thereby avoiding both early and late complications related to percutaneous coronary intervention (PCI) with stent implantation. All the patients will be followed by intracoronary OCT and physiological assessment at 1-month and 12-month follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03062826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ST-segment Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT06654453 — The Thrombus Aspiration During PCI After Thrombolysis in STEMI · NA · recruiting
- NCT03338309 — INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospect · active not recruiting
Other Harbin Medical University trials
Trials by the same sponsor.
- NCT07471815 — Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mecha · Phase 2 · active not recruiting
- NCT07187674 — The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonr · NA · not yet recruiting
- NCT07161791 — Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07033624 — Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study · not yet recruiting
- NCT06947148 — The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03062826 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Harbin Medical University
- Last refreshed: 27 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03062826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing